Researchers provide progression-free survival outcomes for a pancreatic cancer vaccine and safety and efficacy results for a peptide vaccine alone or in combination with pembrolizumab. Two posters ...
In TRuE-AD4 moderate AD, EASI-75 at week 8 favored ruxolitinib over vehicle (70.0% vs 18.5%; P<.0001), with substantial ...
SAN DIEGO and SUZHOU, China, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced data at the ...
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental ...
Over the past 10-12 years the evolution of market leading dye terminator methods and automated capillary electrophoresis instrumentation has largely standardized the procedure for DNA sequencing, ...
Seeking guidance from FDA to proceed towards a Phase 3 clinical study of KETARX™ (ketamine) for Parkinson’s disease under the 505(b)(2) regulatory pathway Ketamine was safe, well-tolerated with 100% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results